In adult humans, haematopoietic stem cells (HSCs) and their progeny are responsible for generating ~1 × 10 9 red blood cells and ~1 × 10 8 white blood cells every hour, including a full complement of platelets and other mature blood lineages. HSCs must also self-renew, and thus must constantly integrate and respond to myriad external inputs to maintain haematopoietic homeostasis. HSCs typically are depicted at the top of a hierarchical 'lineage tree' , each branch point of which indicates a restriction in developmental potential (FIG. 1) .
During mammalian development, haematopoiesis occurs in sequential stages: first primitive, and then definitive, blood formation. These stages are temporally and anatomically distinct, invoking unique cellular and molecular regulators. The formation of primitive blood cells occurs early during fetal life, with coordinated progression from extraembryonic to intraembryonic sites of haematopoiesis. Within the embryo, definitive haematopoiesis undergoes developmentally stereotyped transitions; HSCs arisin g from the aorta-gonad-mesonephros (AGM) region migrate first to the placenta and fetal liver, and then to the spleen. Eventually, haematopoiesis shifts to the bone marrow, where homeostatic blood formation is maintaine d postnatally.
As proposed initially by Schofield 1 in his 1978 description of the regulation of blood formation in the marrow cavity, both primitive and definitive haematopoiesis require input from the cellular microenvironment, or 'niche' . When first proposed, this concept held that a stem cell must associate "with other cells which determine its behaviour" in order to "prevent its maturation" (REF. 1); loss of this association was hypothesized to result in differentiation. This idea has evolved, and the concept of the niche now includes specific cell types, anatomical locations, soluble molecules, signalling cascades and gradients, as well as physical factors, such as shear stress, oxygen tension and temper ature [2] [3] [4] [5] [6] [7] . Inputs from the niche can be permissive of, or conducive to, homeostatic HSC self-renewal and differentiation, but also may constrain normal haematopoiesis under pathological conditions, such as myelodysplasi a, ageing and haematologic malignancy. Yet, the definition of the niche as a microenvironment that provides spatially and temporally coordinated signal s to support stem cell function has remained.
Niches were characterized initially in invertebrate model organisms, such as worms and flies [8] [9] [10] , and subsequently identified in mammals using targeted genetic manipulations [11] [12] [13] [14] [15] . Our conception of the haemato poietic stem cell niche has also been informed by studies in non-haematopoietic tissues, such as the hair follicle, auditory hair cell and intestinal crypt. In these tissues, clear spatial constraints make the identification of niche components more straightforward than in the haematopoietic system, in which blood cells are widely disseminated and constantly in motion 16 . This spatially-defined concept of the niche, which has been derived from anatomically static tissues, has been translated across organisms and tissue types, providing α γ γ γ
Myelodysplasia
General term for haematologic defects involving deficiencies in the myeloid blood lineages, which in fact manifest dysfunction in multiple blood lineages. Myelodysplasias are sometimes referred to as 'preleukaemias' because they can transform over time.
a generalized model for stem cell regulation. However, in certain cases, direct evidence that this model is applicable is still lacking. Nonetheless, it is widely accepted that niches exist in most, if not all, tissues, and that they provide basic cellular necessities, such as mechanical support, trophic factors and hospitable physical and chemical conditions, as well as stem cell-specific self-renewal and differentiation cues (FIG. 2) .
Several new and elegant techniques and model systems have been applied to the study of HSC development, permitting an improved functional and anatomical dissection of HSC interactions with the niche. In particular, real-time in vivo imaging has enabled the direct visual ization of HSCs and their niches, providing key insights into the origins, dynamics and physiological regulation of the anatomical compartments in which Figure 1 | Hierarchical model of haematopoiesis in the adult bone marrow. All haematopoietic cells ultimately derive from a small population of haematopoietic stem cells (HSCs), which is separable into at least two subsets: long-term reconstituting HSCs (LT-HSCs) and short-term reconstituting HSCs (ST-HSCs). LT-HSCs maintain self-renewal and multi-lineage differentiation potential throughout life (represented by the bold arrow). ST-HSCs derive from LT-HSCs and, although they maintain multipotency, they exhibit more-limited self-renewal potential. Further differentiation of ST-HSCs generates multipotent progenitors (MPPs) and then oligopotent progenitors, which are marked with asterisks. Haematopoietic progenitor cells lose their differentiation potential in a stepwise fashion until they eventually generate all of the mature cells of the blood system (these are depicted at the bottom of the schematic). Several potentially distinct subsets of MPPs have been described, but MPPs are shown here as a condensed population for simplicity. Lineage-committed oligopotent progenitors derived from MPPs include the common lymphoid progenitor (CLP), common myeloid progenitor (CMP), megakaryocyte-erythrocyte progenitor (MEP) and granulocyte-monocyte progenitor (GMP) populations. HSC and progenitor populations can be discriminated by flow cytometry, using antibodies that recognize unique combinations of cell surface markers. Some commonly used profiles for identifying these cells are shown adjacent to the HSC and progenitor populations. Dotted arrows denote a proposed lineal connection. CD135, also known as FLK2 and FLT3; IL-7R, interleukin-7 receptor; lin, lineage markers (which are a combination of markers found on mature blood cells but not HSCs or progenitors); NK, natural killer; SCA1, surface cell antigen 1.
Extramedullary
'Outside the marrow.' Used to describe blood formation occurring in anatomical locations that are distinct from the bone marrow. In adults, extramedullary haematopoiesis often signifies haematopoietic stress.
HSCs reside. It is clear now that signals from a range of non-haematopoietic cell types play a coordinated part in ensuring proper HSC function. Moreover, although certain features appear to be common among niches that serve HSCs and those that serve non-HSCs, our improved understanding of the HSC niche underscores important distinctions from the niches found in solid tissues. In particular, haemato poietic niches may not be anatomically restricted, and the signals provided to HSCs may be spatially, as well as temporally, compartmentalized. Thus, altering either the location or the timin g of niche-dependent signalling may initiate divergent developmenta l outcomes.
In this Review, we discuss the HSC niche from an ontogenic perspective. We address current theories and open questions surrounding niche cells and their role in regulating fetal and adult definitive haematopoiesis. HSC biology is a rapidly expanding field, and recent advances have increased interest in the fundamental biology of these cells and in their potential as a source material for gene and cell therapy. Deeper understanding of the signals that stem cells receive from their niche as they grow and differentiate is essential for optimizing their therapeutic benefit.
Vertebrate haematopoiesis
Vertebrate haematopoiesis takes place in ontogenic waves. In both fish and mammals there are primitive phases, in which blood stem cells produce only a subset of specialized blood lineages, and definitive phases, in which true HSCs appear. In zebrafish, at least three distinct phases of haematopoietic development exist, and in mammals there are at least two. Primitive haemato poiesis is first detected extra-embryonically, in the yolk sac, as early as embryonic day 7.5 (E7.5) in mice and 30 days post-conception (dpc) in humans [17] [18] [19] (FIG. 3) . Although evidence exists that cells isolated from the yolk sac can reconstitute haematopoiesis fully 20, 21 , it has recently become clear that multipotent HSCs also emerge directly from the AGM region (at E10.5 in mice 22, 23 and 4 weeks pc (wpc) in humans 24 ) to initiate definitive haematopoiesis. In all studied vertebrates, in fact, the first HSCs arise from the ventral wall of the dorsal aorta [25] [26] [27] [28] [29] [30] , although they subsequently seed additional tissues and organs in a species-specific manner. In mammals, haematopoiesis moves from the AGM to the placenta and fetal liver; for example, by E11-E12 in mice and by 5 wpc in humans. Haematopoiesis in mice shifts to the spleen by E14 and begins to shift to the bone marrow by E18; in humans, it moves from the fetal liver to the bone marrow at 12 wpc. By birth in humans, the bone marro w supports the vast majority of haematopoiesis, and extramedullary multi lineage haematopoiesis is negligible except in cases of pathology. By contrast, in mice, splenic haematopoiesis persists for several weeks postnatally 31 . Finally, in fish, the kidney serves as the predominant site of haematopoiesis in adult life.
The molecular underpinnings of the dynamic progression of blood cell formation during development are complex and still under investigation (see below). It is clear that many cytokines influence the differentiation and proliferation of haematopoietic stem and progenitor cells (HSPCs; a designation which includes HSCs and multipotent and oligopotent progenitors). However, only a few have been demonstrated genetically to be necessary for HSC maintenance in vivo; these have been reviewed extensively elsewhere [32] [33] [34] and include angiopoietin 35 , CXC chemokine ligand 12 (CXCL12; also known as SDF1) 36, 37 , stem cell factor (SCF; also known as steel factor and KIT ligand) 38 and thrombopoietin 39, 40 . In addition, developmental mediators, such as Notch (reviewed in REF. 41 ) and WNT (reviewed in REF. 42 ), are important for HSC maintenance. Other membranebound receptors, such as integrins 43 and cadherins 44 , may also contribute. Many of these cytokines and developmental regulators are produced by niche cells and by haematopoietic cells. 'Niches' provide physical support, soluble factors and cell-mediated interactions to maintain and regulate the function of haematopoietic stem cells (HSCs). In addition, they can provide physical conditions that are conducive to stem cell renewal and differentiation. This schematic represents many of the factors that have been shown recently to be important in the bone marrow haematopoietic niche. Because cytokines and cell surface adhesion molecules have been reviewed extensively elsewhere 33, 34, 44, 59, 66, 67 , they are depicted only generally in this schematic. Instead, this figure emphasizes the many distinct cell populations that contribute to HSC regulation by the niche, and the critical chemical, physical and mechanical signals that can modulate HSC behaviour, including temperature, shear forces, oxygen tension and monoatomic ions, such as Ca 2+ . This image is not intended to provide a comprehensive illustration of relevant niche factors. CAR, CXCL12-abundant reticular; GPCR, G protein-coupled receptor; MPP, multipotent progenitor; MSC, mesenchymal stem cell; RTK, receptor Tyr kinase.
Haemogenic endothelium
A layer of committed endothelial cells that have the capacity to differentiate into blood cells, losing endothelial characteristics and adopting haematopoietic features.
Haemangioblast
An undifferentiated precursor cell formed during development that has the potential to give rise (at the single cell level) to blood cells and endothelial cells, but not to other cell lineages.
HSCs require interactions with distinct niches at each stage of ontogeny. Thus, the sequential exposure of HSCs to different extracellular cues may have an important influence on their development and maturation; alternatively, perhaps the common features among these niches are exploited by HSCs to support their function in other wise varied environments. Either way, the anatomical relocalization of HSCs during development imparts unique challenges for the niches that support them and suggests that haematopoietic niches may be one of the most dynamic of stem cell-supportive niches.
The niche in fetal haematopoiesis
It has recently become possible to visualize individual HSCs arising from endothelial cells (ECs) of the ventral aspect of the dorsal aorta using direct in vivo imaging techniques 22, 45 . These imaging data provide strong support for the haemogenic endothelium hypothesis 46, 47 , which posits that HSCs arise directly from committed ECs. The haemogenic endothelium model is related to, but distinct from, the haemangioblast hypothesis, which supposes the existence of a common, bipotent precursor that gives rise to both the vasculature and the blood cells during development. Aside from the implications of this work with respect to the origin of HSCs, these imaging studies also argue that the niche for the very earliest HSCs is provided by the very same cells that give rise to those HSCs (FIG. 4) .
Newly-formed HSCs emerging from the ventral aspect of the dorsal aorta in the AGM either bud off into the aortic circulation or remain embedded within the endothelium 22, 28, 45 . The ECs that do not convert to HSCs are capable of supporting HSCs in vitro 48 . One group has undertaken gene expression profiling of the haematopoietic AGM region and performed in situ hybridization to corroborate the results. Although it is difficult to identify cells definitively by in situ analysis of embryo sections, these experiments seem to suggest that p57 (also known as KIP2 and CDKN1C) and insulin-like growth factor 2 (IGF2) are upregulated in ECs underlying emerging HSCs 49 . It remains unclear, however, precisely how these niche factors influenc e HSC function. p57 is a cyclin-dependent kinase inhibitor expressed in adult HSCs 50 and it is difficult to envision a cell-extrinsic role for this protein in HSC function. By contrast, IGF2 is a secreted growth facto r, and culture of HSCs with IGF2 increases the frequency of mixed and erythroid colonies and decreases the frequency of macrophage and granulocyte-macrophage colonies in methylcellulose culture. These data led the authors to conclude that IGF2 signalling promotes the maintenance of primitive multipotent cells and early erythroid precursors at the expense of more mature myeloid precursors 49 . Whatever mechanisms underlie the haemato poietic regulatory function of haemogenic endothelium, these ultimately vanish when distinct somitic endothelial precursors migrate to the ventral aspect of the dorsal aorta and replace the haemogenic endothelium, an event that coincides with the disappearance of haematopoietic potential from the AGM 51 . Within half a day of the emergence of HSCs from the ventral aortic endothelium, they can be found in the yolk sac, placenta and fetal liver. Quantitative analysis suggests that HSCs are independently generated in the yolk sac, placenta and AGM, and cells generated in all of these anatomical sites may colonize the fetal liver [52] [53] [54] . The mechanistic basis for HSC emergence in the yolk sac and placenta has not been defined, although by analogy with the AGM, HSCs here might also arise locally from developmentally regulated haemogenic endothelium. Likewise, the factors responsible for the subsequent engraftment of HSCs in the fetal liver are still being eluci dated. The chemokine CXCL12, which is expressed by stromal cells, and its G protein-coupled receptor CXC chemokine receptor 4 (CXCR4; also known as fusin and CD184), which is expressed on haematopoietic cells and some cancer cells, are clearly important for proper HSC function and migration, including HSC engraftment into the fetal liver 36, 55, 56 . Likewise, the cytokine SCF, which is produced by stromal cells, and its receptor KIT (also known as CD117 and SCFR), which is expressed on pluripotent haematopoietic cells, have long been recognized as critical for HSC function [57] [58] [59] .
SCF-KIT signalling also appears to amplify the migratory response of fetal HSCs to CXCL12 (REF. 57 ). Additional factors that have been suggested to be important for fetal HSC migration and engraftment include α4 integrin 43 , neural cadherin (N-cadherin) and osteopontin 60 , which are membrane-bound adhesion molecules that can activate WNT signalling. Other factors, such as the transcription factor pituitary homeobox 2 (PITX2), must be expressed in stromal cells in order to support normal fetal HSC function and maintenance, although the mechanism underlying this effect remains unclear 61 . More recently, BRG1-associated factor 250A (BAF250A; also known as ARID1A), a SWI/ SNF (switch/sucrose nonfermentable) family member, has been shown to restrict HSC expansion in the fetal liver in a cell-non-autonomous fashion 62 . BAF250A might accomplish this by altering HSC-stromal cell inter actions to reduce HSC expression of self-renewal and survival factors and enhance expression of genes associate d with senescence and apoptosis 62 . At about E17.5 in the mouse, fetal haemato poiesis moves to the bone marrow 57 . This relocalization is thought to result from the development, at around E14.5, of osteoblast and chondrocyte precursor cells that are capable of forming an HSC niche 63 . The signals that are responsible for transferring the bulk of haematopoiesis from the liver to the bone marrow are not entirely understood. However, CXCL12-CXCR4, SCF-KIT, TIE2-angiopoietin, integrin and CD44-epithelial cadherin (E-cadherin) adhesion and signalling pathways appear to be important for this process 44 and for retaining HSCs within the marrow space 64 . In addition, transformation of the liver into a synthetic and digestive organ, which is marked by the differentiation of hepatoblasts into hepatocytes, beginning at about E15.5 in the mouse , probably results in the replacement of haematopoietic niches with hepatic functional units. This change might drive the relocation of fetal liver HSCs to the bone marrow, where HSC-niche cell relationships enter their adult phase (discussed further below).
Taken together, these recent and historical findings support a co-developmental model of HSC-niche cell interactions throughout ontogeny, wherein haematopoiesis in a new niche occurs concurrently with the matur ation of that niche's ability to support haematopoiesis. This model also implies that the waning of haemato poiesis in a particular ontogenic niche may result from the execution of a developmental programme that makes the prior niche inhospitable (FIG. 4) , or from the emergence of a new, more 'attractive' niche.
Acellular factors in the adult niche
In postnatal life, the bone marrow represents the primary reservoir for HSCs and haematopoietic progenitors in both mice and humans. The activity of adult HSCs is carefully regulated by a number of different signals, including many of the cytokines discussed above. Many non-proteinaceous factors, including calcium ions, oxygen tension and reactive oxygen species, also are critical for proper HSC regulation, although such elements have only recently been integrated into the However, the pulsatile nature of arterial circulation, coupled with the finding that shear stress upregulates Runx1 (a transcription factor known to be critical for developmental haematopoiesis) in fetal HSCs, suggests that this process may be regulated, at least in part, by blood flow. c | Over time, haemogenic endothelium is replaced by non-haemogenic endothelial cells (green) that migrate from periaortic somites, remodelling the haematopoietic niche so that it no longer supports the emergence or maintenance of HSCs. The signals that mediate this migration are unclear. AGM, aorta-gonad-mesonephros.
Long-term HSCs
(Long-term haematopoietic stem cells; LT-HSCs). Cells that are capable of nearly indefinite self-renewal and differentiation into the mature cells of blood lineages (as assayed by transplantation). These are the bona fide stem cells of haematopoiesis. They are operationally distinct from short-term HSCs, which are capable of only limited self-renewal (but competent to differentiate into the mature cells of all blood lineages) and therefore cannot reconstitute haematopoiesis for the life of an organism.
Cancellous bone
(Also known as trabecular bone). The spongy osseous tissue located at the ends of long bones and within vertebral bodies. It contains haematopoietic (red) marrow but, unlike the medullary cavity of the long bones, also contains trabeculae (tiny osseous beams that traverse the cancellous bone, creating an anatomical and functional structure through which blood and bone marrow elements transit).
Homing
The process whereby haematopoietic stem cells (HSCs) find their way from the circulation to the haematopoietic 'niche' . It is distinct from lodgement, which is the ability of HSCs to enter into the niche and stay there, as well as from engraftment, which is the ability of HSCs to respond to appropriate maintenance and differentiation signals when lodged.
Endosteal structures
Elements of the endosteum, which is a connective-tissue membrane that lines the inner surface of the medullary (marrow) cavity of the bone. Many researchers also refer to the endosteum as the inner surfaces of the bone (that is, the location of osteoblasts; see the glossary entry for osteoid cells).
concept of the bone marrow niche. In addition, physical and mechanical inputs, such as shear force and rigidity, are becoming better defined as contributors to niche haemato poiesis. As the role of cytokines in the adult HSC niche has been extensively reviewed by others 33, 34, 44, 59, 66, 67 , we focus here on some of the more-recently identified non-cytokine niche components that are implicated in adult haematopoiesis.
Oxygen tension regulates HSC function. It was suggested several years ago that long-term HSCs (LT-HSCs) reside in a hypoxic niche, with initial studies relying upon Hoechst dye staining as a proxy for perfusion (more intense staining correlates with better perfusion, which presumably correlates with increased oxygenation). These studies did not examine the marrow compartment anatomically; however, subsequent staining with pimonidazole, a chemical marker for hypoxia, confirmed that HSCs were in fact hypoxic 68 . Later studies combined the creative use of Hoechst dye as a hypoxia marker with conventional cell-surface immuno phenotyping to evaluate the cellular environment in which HSCs reside. These studies suggested that LT-HSCs are found predominantly in poorly-perfused niches. Moreover, co-staining for mesenchymal stem cells (MSCs), osteoblasts, and vascular ECs revealed that, of these, only osteoblasts are similarly located in poorly-perfused niches; ECs and MSCs (as well as a subset of osteoblasts) were judged to show medium to high staining with Hoechst dye, indicating good perfusion 69 . Unfortunately, these experiments did not couple hypoxia (as measured by the Hoechst dye gradien t) to bone marrow anatomy. Thus, these findings provide only indirect evidence that the most quiescent LT-HSCs coexist with osteoblasts in a region far from an oxygenated blood supply.
A recent study in humans, in which bone marrow vasculature was visually compared to anatomically localized HSPCs, demonstrated that most blood vessel fragments in cancellous bone exist within 50 μm of the trabecular surface 70 . This study also demonstrated that most HSPCs exist within 200 μm of a blood vessel fragment. Because oxygen tension could not be assessed in this study, it is unclear how to reconcile these findings with the Hoechst experiments discussed above. However, unpublished data from the Silberstein laboratory show direct visualization of a hypoxic HSC (using pimonidazole) in close proximity to vascular structures as well as a non-hypoxic B220 + B cell (L. Silberstein, personal communication). Such data indicate that, although HSCs may indeed be hypoxic, their hypoxic state may be less determined by the niche in which they reside and more by a function of some quality that is intrinsic to the HSCs. Consistent with this notion, recent studies on HSCs themselves support the importance of hypoxia for HSC maintenance 71, 72 and, further, suggest that hypoxic regulation must keep the levels of hypoxia-inducible facto r 1α (HIF1α; a transcription factor that is upregulated in mammalian cells growing at low oxygen concentrations) within a certain window. Hypoxic upregulation of HIF1α in HSCs causes a shift away from mitochondrial oxidative phosphorylation and towards glycolysis, which promotes HSC survival in a hypoxic microenvironment 73 . However, deletion of HIF1α leads to HSC proliferation and an eventual exhaustion of repopulating capacity, particularly in conditions of haematopoietic stress 72 ; paradoxically, overstabilization of HIF1α also leads to HSC loss 72 . Thus, there may exist a narrow window in which the niche is neither too hypoxic nor too hyperoxic and oxygen tension is optimal for HSC maintenance and function. The anatomical localization of this region may be determined by both distance from bone marrow vascular sinuses and HSC-intrinsic signalling. Continued exploitation of newly-developed imaging techniques that permit realtime, in vivo imaging of anatomical and functional niche components [74] [75] [76] should soon enable combined mapping of anatomical and physical niche factors, allowing definitive conclusions about the relationship between anatomical location and HSC hypoxia within the bone marrow microenvironment.
Calcium regulates HSC function. Deletion of the calcium ion-sensing receptor in HSCs prevents them from lodging efficiently in the bone marrow and decreases marrow cellularity 77 . Further studies indicate that pharmacologic stimulation of the calcium ion-sensing receptor improves HSC homing to bone marrow and subsequent engraftment 78 , suggesting that calcium ions act as chemoattractants to HSCs. Additionally, inhibition of osteoclasts, the primary liberators of calcium ions in bone, by bisphosphonates decreases HSC numbers and engraftment 79 . However, osteoclasts also can promote HSPC mobilization through effacement of endosteal structures 80 , reflecting a complex and context-dependent role for divalent cations in regulating haematopoiesis.
Shear force and mechanical support regulate HSCs. It has been shown recently that the circulatory shear stress to which fetal HSCs are subjected in the developing dorsal aorta upregulates nitric oxide-mediated Runx1 transcription 5 . RUNX1 is a well-described transcription factor that regulates the haemato poietic programme 81 . Although the adult bone marrow and dorsal aorta are quite distinct, the bone marrow is exposed to, and continuous with, the circulatory system. It is therefore quite possible that blood flow through the marrow cavity has a role in adult haematopoiesis as well. Additionally, the quality of mechanical support given by the extracellular matrix to many other types of stem cells has been demonstrated to affect their differentiation [82] [83] [84] . Thus, in addition to influencing haematopoiesis secondarily, the physical properties of matrix components may directly affect HSC function.
Cellular factors in the adult niche
The main function of the bone marrow is to provide new blood cells, as needed, throughout life. The bone marrow is highly complex, and conventional representations of bone marrow haematopoiesis often reference an 'endosteal niche' , which is populated by osteoblasts, and a 'vascular niche' , which is an anatomically distinct perivascular space. However, this concept is almost certainly an over-simplification. Recent advances have
Osteoid cells
Cells of the bone lineage: osteocytes, osteoblasts and their precursors. Osteoclasts are not osteoid cells, as they are haematopoietic in origin. Anatomically, osteoid is the unmineralized immature bone matrix laid down by osteoblasts and containing osteocytes.
CXCL12-abundant reticular cells
(CAR cells). Cells that were originally identified on the basis of their high expression of CXC chemokine ligand 12 (CXCL12). CAR cells can be perivascular or endosteal in location.
refined our understanding of how HSCs interact with niche cells, of which cell types have niche functions and of how acellular aspects of the microenvironment affect haematopoiesis. Further evidence indicates that a single HSC can receive input simultaneously from multiple, distinct types of niche cells and that HSCs may move among these niches quite readily, data that potentially collapse models based on anatomically separate niches (see the discussion below on osteoblasts and other niche cells). In aggregate, these studies suggest a new model of marrow haematopoiesis, in which one may visualize the entire bone marrow compartment as a niche, with discrete areas and cellular elements serving distinct functions at different stages of haematopoietic development and differentiation. In this section, we review recent advances in our understanding of the specific cell types that constitute the bone marrow niche and how these cells interact with HSCs.
Osteoblasts: canonical niche cells. Bone-forming osteoblasts interact with HSCs at the interface between the bone and the marrow space, in what has been termed the endosteal niche. The osteoblast is arguably the bestcharacter ized of all HSC niche cells. Genetic experiments that increase osteoblast numbers result in increased HSC numbers 14 , and osteoblast ablation ultimately results in the loss of HSCs 85, 86 . Although osteoblasts certainly can act as positive regulators of HSC function, the mechanisms underlying that regulation are not entirely clear. Osteoblasts secrete cytokines, such as granulocyte colony-stimulating factor (G-CSF), granulocyt emacrophage CSF (GM-CSF) and interleukin-6 (IL-6) 87 , which support HSC survival and differentiation. Osteoblasts also express factors that regulate HSC numbers, including angiopoietin, thrombopoietin, WNT, Notch, N-cadherin and osteopontin 40, [87] [88] [89] [90] [91] [92] [93] [94] [95] , although it is still unknown how these diverse signals are integrated into a central programme. Interestingly, experiments in which micro RNA (miRNA) processing was impaired specifically in osteoblast precursors, through cell-specifi c deletion of the essential miRNA processing enzyme Dicer, resulted in perturbed haematopoiesis and the onset of a myelodysplasia-like phenomenon 96 . By contrast, Dicer disruption in mature osteoblasts yielded a bone phenotype but no overt changes in haematopoiesis, suggesting stage-specific interactions between this niche cell lineage and HSCs
96
. Co-culture experiments further demonstrate the ability of osteoblastic cells to support and maintain HSC growth and function 87, 97, 98 , confirming functionally their role as HSC niche cells. Two groups recently showed that culture of HSCs with endosteal cells, isolated on the basis of various cell surface markers, is sufficient to maintain long-term reconstituting capacity (that is, the ability of HSCs to reconstitute fully all blood lineages for the life of the organism) 97, 98 . Also, these groups demonstrated that the endosteal population is heterogeneous, capable of differentiating in vitro into osteoblasts, adipocytes and chondrocytes, and that these subtypes have a differential ability to support HSC function. The chondrogenic population was the least effective at supporting HSCs and the osteoblastic population was the most effective. The superior function of osteoid cells in these assays may reflect their documented ability to produce multiple signalling molecules that are important in niche-HSC interaction, including Notch and CXCR4 (REFS 14, 41, (99) (100) (101) .
The relevance of the in vitro studies described above to the physiological regulation of HSCs has been corroborated recently by in vivo imaging studies, which permit real-time, direct, in vivo observation of HSCs interacting with niche cells and indicate a close physical proximity of HSCs to osteolineage cells 76 . Likewise, studies using advanced confocal techniques to achieve fine-resolution three-dimensional mapping of the endosteal niche 74 document a close association between newly-engrafted LT-HSCs and the endosteum, whereas more mature haematopoietic progenitor cells do not associate as closely with osteoblasts 75, 76, 102, 103 . Yet, in contrast to previous models, which considered the osteoblastic niche to be anatomically distinct from other niches (see below), imaging data from the Scadden 76 and Silberstein groups (L. Silberstein, personal communication) demonstrate that, although LT-HSCs preferentially lodge close to the endosteum after transplantation, this location typically is proximate to perivascular cells as well, both in the calvarium and the long bones. Thus, it is possible for a single HSC to inhabit simultaneously what had previously been considered to be two discrete haematopoietic niches. Of course, a significant caveat to these imaging studies is that they rely on the transplantation of marked (usually with green fluorescent protein (GFP)) HSCs, and such transplantation models may not reflect the true physiology of endogenous HSCs. It also is notable that technical limitations prohibited the concomitant cell-surface staining of visualized HSCs, limiting the investigators' ability to place these cells in a developmental hierarchy with high resolution. Nonetheless, these provocative findings suggest a less anatomically rigid concept of the HSC niche than that currently considered to operate in solid tissue systems.
Various cell types make up the vascular niche. In addition to osteoblasts, HSCs in the adult bone marrow associate with vascular structures within the marrow cavity. As these structures represent the gateway through which blood cells, including HSCs 16 , must pass when transiting into or out of the bloodstream, they are clearly candidates for transducing migration, engraftment and differentiation signals to HSCs. Proximity to the vasculature might also facilitate the sensing of systemic signals by medullary HSCs, which would allow the coordination of blood-forming activity in haematopoietic tissues that are spread throughout the body.
Several cell types within the perivascular space, including perivascular MSCs, CXCL12-abundant reticular cells (CAR cells) and neural cells, have been reported to act independently to regulate HSC function. Because most of these perivascular cells have been identified on the basis of non-overlapping or partially-overlapping sets of markers, there is some question as to how distinct these cells really are. It is possible, and even likely, that some of these α reported marker systems identify overlapping populations of cells, or that they mark cells at multiple, discrete stages of differentiation within the same lineage.
An elegant set of experiments 104 recently implicated a population of perivascular nestin-expressing (NES + ) MSCs in the regulation of HSC function. Ablation of these NES + cells using an inducible system reduced the number of LT-HSCs in the bone marrow by 50% between 6 and 14 days after ablation. NES + cells express high levels of CXCL12, which is known to regulate HSC migration 105, 106 , and they are closely associated with sympathetic nerve fibres, which are themselves able to regulate cytokine-induced mobilization of HSCs from the bone marrow 107 . NES + MSCs can be differentiated into adipocytes, osteoblasts and chondrocytes, and their HSC regulatory function is modified by sympathectomy or by treatment with G-CSF (which downregulates their ability to express CXCL12, SCF, angiopoietin, IL7, and vascular cell adhesion molecule 1 (VCAM1)). Together, these findings strongly suggest that niche-dependent regulation of HSCs occurs coincidently with niche cell differentiation, as has previously been demonstrated in the interactions of developing B cells with osteoblasts 108, 109 . Thus, as stromal cells migrate, differentiate and undergo changes in gene expression in response to developmental or physiological cues, the impact that they have on haemato poiesis is also likely to change.
A series of investigations 110 paralleling the studies on NES + cells has focused on the previously-identified population of CAR cells. These CAR cells were ablated from mice using an inducible system in which a transgene encoding the diphtheria toxin receptor fused to GFP was inserted into the CXCL12 locus. Treatment of these mice with diphtheria toxin allowed the specific deletion of CXCL12-expressing cells and, although the mice died from liver failure 5 days after toxin administration, they demonstrated a severe reduction in CAR cells before death (at 2-3 days after injection). This loss of CAR cells coincided with a 50% reduction in LT-HSC number 110 . In addition, LT-HSCs in CAR cell-depleted mice were smaller and less-actively cycling, suggesting that the LT-HSCs that remained in these animals were more quiescent than in control mice. Multipotent progenito r (MPP) cell numbers appeared normal in these mice, as they did when CXCR4 was ablated in adult mice by the same group 37 . However, CAR cell-depleted animals showed significant reductions in the number of megakaryocyte-erythroid progenitors (MEPs), granulocyt emonocyte precursors (GMPs), and common lymphoid progenitors (CLPs) -cell types that are derived from MPPs (FIG. 1) . CAR cells differentiate, in vitro, into adipocytes and osteoblasts, and treatment with the myeloablative agent 5-fluorouracil induced CAR cells to preferentially adopt an adipocyte cell fate in vivo. Thus, like the NES + cells discussed above, CAR cells exhibit MSC characteristics, although the degree of overlap between CAR cells and the NES + cells is not yet known. One significant difference between the two cell types is that CAR cells, although predominantly peri vascular, are also located at the endosteal surface, whereas NES + cells are reported to be exclusively perivascular 104 . Related to both of these putative niche cell populations, a recent report described the isolation of bone-lining cells that support HSCs and can differentiate in vitro into both adipocytes and osteoblasts, although these cells have poor chondrogenic potential 98 . The lineal relationship between these three sets of putative niche cells (perivascular tripotential NES + cells, perivascular bipotential or tripotential CAR cells and endosteal bipotential precursor s, see FIG. 5) remains to be elucidated.
Accumulating evidence supports the critical role of marrow innervation in moderating the function of HSCs and their interaction with other niche cells. HSC activity seems to be regulated by both the sympathetic and , mesenchymal stem cells (MSCs) 104 and surface cell antigen 1-expressing (SCA1 + ) bone-lining cells 98 (labelled endosteal precursor). The factors secreted by these cells that can regulate HSCs are shown in yellow boxes and the cell surface markers that they express are listed in grey boxes. The cell types that these mesenchymal cells can differentiate into, determined largely by in vitro differentiation assays, are indicated by the solid arrows. It is unclear whether CAR cells can differentiate into chondrocytes (dotted arrow). ALCAM, activated leukocyte cell adhesion molecule; ANGPT, angiopoietin; CD135, also known as FLK2 and FLT3; CXCL12, CXC chemokine ligand 12; ENG, endoglin; IL-7, interleukin-7; JAG1, Jagged 1; N-cadherin, neural cadherin; NES, nestin; PDGFRα, platelet-derived growth factor receptor-α; PECAM1, platelet endothelial cell adhesion molecule 1; SCF, stem cell factor; THPO, thrombopoietin; VCAM1, vascular cell adhesion molecule 1.
Vascular sinusoid
A fenestrated capillary-sized blood vessel. Sinusoids are quite porous, permitting the free passage of many blood components.
Parabiosis
A surgical procedure whereby the circulatory systems of two animals are joined such that there is free flow of blood between them.
the parasympathetic systems. This regulation clearly can occur indirectly, as both sympathetic receptor blockade and sympathectomy affect stromal cell numbers and function 107 . However, human HSPCs also express and respond to signalling through dopaminergic and adrenergic receptors 111, 112 , indicating that direct neural inputs could regulate HSC activity.
Early studies using static imaging of immunofluorescently marked HSCs 13 had suggested that ECs might regulate HSCs in the marrow and the spleen, based on their close anatomical proximity. This hypothesis has gained further support from more-recent studies that identify true vascular ECs as important HSC niche components 113, 114 . ECs can be distinguished from other bone marrow perivascular cells by their lack of surface cell antigen 1 (SCA1) expression. Marrow ECs also express the vascular markers vascular endothelial growth factor receptor (VEGFR; subtypes 2 and 3), platelet EC adhesion molecule (PECAM1; also known as CD31) and vascular endothelial cadherin (VE-cadherin; also known as CD144). Initial characterization of ECs used antibodymediated in vivo disruption of VEGFR signalling to target ECs in recipient mice, which resulted in poor engraftment of transplanted donor bone marrow cells 115 . However, this result could theoretically arise from indirect inhibition of vascular sinusoid-associated non-EC cells, so direct assessment of the ability of ECs to support haematopoiesis was needed to verify this finding. Unfortunately, sinusoidal ECs are impossible to culture from bone marrow without manipulation, and subsequent in vitro studies have had to rely on semi-immortalized transfected human umbilical vein ECs (HUVECs). HUVECs transfected with the adenovirus E4 gene E4ORF1, which constitutively activates AKT1 (REF. 114 ), secrete factors that are important to non-angiogenic tissue growth, such as IGFbinding protein 2 (IGFBP2), bone morphogenic protein 4 (BMP4) and fibroblast growth factor 2 (FGF2). These transfected ECs signal through the Notch and angiopoietin pathways to support and maintain LT-HSCs. By contrast, ECs transfected with a constitutively-active RAF construct, which activates the mitogen-activated protein kinase (MAPK) pathway, downregulate stem cell maintenance factors and upregulate factors that promote HSPC expansion and differentiation, such as IL-6, angiogenin 2 and Notch ligands. These data strongly suggest that ECs are competent to fulfil haematopoietic niche activities; however, direct functional validation of this conclusion in vivo is still needed.
In light of the identification of many distinct perivascular stromal cells that are capable of affecting haematopoiesis, and the new knowledge that HSCs are frequently positioned in close proximity to both osteoblasts and vascular structures, a more holistic model of the niche is required, in which HSCs may simultaneously interact with, and respond to, multiple different niche cell inputs. Further studies that define precisely how each of the many perivascular cell types described above interacts with HSCs, with each other and with other elements of the marrow microenvironment will help to clarify the complicated and tightly regulated developmenta l programme that controls haematopoiesis.
Negative regulation of HSCs by adipocytes. In addition to the osteolineage and perivascular cells discussed above, the bone marrow contains lipid-storing adipocytes, the abundance of which increases with age and obesity, and after haematotoxic injuries, such as chemotherapy or irradiation [116] [117] [118] [119] [120] . Only recently has it become clear that, far from simply filling space in the marrow, adipocytes actively and directly regulate HSC function, apparently in a negative manner. This observation stems most convincingly from work in which HSCs isolated from adipocyte-rich tail vertebrae showed reduced activity in transplantation assays, as compared to HSCs isolated from adipocyte-poor thoracic vertebrae 121 . Additionally, inhibition of adipogenesis by genetic or pharmacologic interventions resulted in improved HSC function. Recognizing that reduced adipogenesis is accompanied by increased osteogenesis in their systems, the researchers also attempted to study the adipocytic interaction in isolation, by culturing HSCs with adipocyte-differentiated OP9 stromal cells. Such cultures resulted in poorer HSC function. Complementing these findings, studies of obese leptin-deficient mice (ob/ ob mice) 122 and leptin receptordeficient mice (db/ db mice) 123 indicate that these animals exhibit impaired haematopoiesis, with relative bone marrow hypocellularity and myeloid skewing. Intriguingly, at least some of these defects can be ameliorated when db/ db mice are joined to wild-type partners in parabiosis for four weeks, thereby exposing them to a non-obese systemic circulation 123 . These data may indicate the presence of systemic factors in non-obese mice that can overcome HSC suppression by the obese niche, even though hyperglycaemia and elevated insulin levels in db/db partners were not lowered by parabiosis 123 . Alternatively, because these analyses focused on peripheral blood and not bone marrow, these results could reflect effects on more mature cells, such as the transiting of circulating precursor cells through the non-obese circulation.
Finally, studies in which both osteoblasts and adipocyt e-containing bone marrow stromal cells were isolated demonstrate a significant negative influence of adipocytic cells on the ex vivo proliferation and haematopoietic colony-forming ability of HSPCs 97 . This suppression could not be overcome in mixed osteoblas t-stromal cell cultures and may relate to the elevated expression of neuropilin 1 (NRP1), a non-classic VEGF and semaphorin receptor that is important in both angiogenesis and neuronal cell guidance 97 . NRP1 has been shown in cell culture to inhibit granulopoiesis and promote myelopoiesis from human CD34 + cells via inhibition of G-CSF production 124 , and NRP1 expression was elevated in the inhibitory stromal cell fraction, suggesting that its overproduction by adipocytic stromal cells may contribute to their dominant inhibition of haematopoietic activity.
Taken together, the studies discussed above strongly suggest that adipocytes mediate a direct, inhibitory effect on HSC function. However, the fact that adipocytes and osteoblasts coexist in dynamic opposition, with adipocyte numbers increasing when osteoblast numbers decrease (and vice versa), and that adipocytes and osteoblasts sometimes derive from the same precursor cell,
Non-homologous end joining
A double-strand DNA break repair mechanism that does not make use of a homologous DNA template and is therefore more error-prone than homologous recombination.
complicates efforts to isolate the specific contribution (or contributions) of each cell type. In in vivo studies, effects attributed to one cell type may be partially influenced or overshadowed by the absence of an opposing effect of the other cell type. New systems are needed to enable the examination or manipulation of each cell type in isolation in order to distinguish their direct effects on HSCs. In any event, existing data provide an emerging picture of the HSC niche, suggesting that it must invoke complex interactions between many different stromal cell types to explain the dynamic regulation of marrow haematopoiesis.
The niche in dysregulated haematopoiesis
Although most haematopoietic malignancies are likely to arise from mutations that inappropriately activate haematopoietic cell proliferation and survival pathways, recent data demonstrate that haematopoiesis can also be dysregulated by alterations in the niche, with defects in HSCs themselves arising secondarily. The most compelling recent example comes from work in which miRNA processing was disrupted in osteoblast precursors and mice developed myelodysplasia, which in rare cases progressed to myeloid leukaemia by 3 weeks of age 96 . Notably, HSCs transplanted from these mice into wild-type recipients did not transfer myelodysplasia, indicating that the HSCs were not intrinsically competent to produce pathologic changes. Similarly, APC min (adenomatosis polyposis coli, multiple intestinal neoplasia) mice, which are heterozygous for a truncated, nonfunctional allele of the tumour suppressor and negative regulator of canonical WNT signalling APC, develop myelodysplasia as they age, and this phenotype is not rescued by transplanting wild-type CD45.1 bone marrow 125 . Of note, these transplantation experiments used sublethally-irradiated recipients, leaving open the possibility that the continued formation of blood cells from residual APC min HSPCs contributed to the development of myelodysplasia in these animals. Nonetheless, these studies add to a growing body of evidence indicating that malignancy and premalignancy can arise from microenvironmental defects 126, 127 , or from cooperation between haematopoietic and niche cells. This appears to be the case for the myeloproliferation that develops in mice deficient in the retinoblastoma (RB) protein; haematopoietic dysfunction in this model requires deletion of Rb in both niche cells and myeloid cells 127 .
Other suggestions of microenvironmentally-driven haematopoietic dysfunction come from the literature on ageing. Ageing is accompanied by well-described haematopoietic changes, including the accumulation of phenotypic HSCs with diminished repopulating capacity, as well as a propensity towards myelopoiesis instead of lymphopoiesis [128] [129] [130] [131] [132] [133] . Although HSC-intrinsic changes undoubtedly contribute to these age-associated phenotypes 131 , changes also occur in the microenvironment over time 133 . For instance, mammalian target of rapamycin (mTOR) signalling is increased in aged HSCs, presumably as a result of microenvironmental cues 134 . Heightened mTOR signalling in aged HSCs suppresses their engraftment function and appears to contribute to age-dependent deficits in immune function 134 . Additionally, recent proteomic analysis of bone marrow stromal cells in culture demonstrates that older stromal cells produce more hydrogen peroxide than younger cells 135 , which could lead to increased production of oxygen free radicals. This potentially more-toxic environment may have deleterious effects on HSC function.
Toxic insults that cause DNA damage, such as ionizing radiation, might also adversely affect haematopoiesis, in part owing to the preferential use of particular DNA damage response mechanisms in HSCs. Quiescent HSCs preferentially use non-homologou s end joining in response to radiation-induced DNA damage, and this repair pathway is prone to introducing base deletions and additions 136, 137 . Irradiation also has profound effects on niche cells themselves, including osteoblasts and adipocytes. Although the marrow space becomes infiltrated by adipocytes soon after irradiation 119, 138 , the first response to a radiation insult is a transient and reversible proliferation of osteoblasts, which peaks at 48 hours postirradiation and disappears by 10 days post-transplant 139 . Interestingly, emerging data indicate that irradiation is more disruptive of bone marrow architecture than chemotherapy (J. R. Harris, J. P. Chute and T. Reya, personal communication). The administration of cyclophosphamide to mice at conventional doses resulted in severe myelotoxicity but significantly less damage to the bone marrow architecture in comparison to radiation, which caused extensive destruction of both haematopoietic cells and bone marrow stromal cells, as well as delayed haematologic recovery. These findings suggest that systemic toxins are likely to have very distinct deleterious effects on HSCs and stromal cells.
Finally, obesity in humans has been correlated both with changes in the bone marrow microenvironment 120 and with an increased incidence of haematologic malignancy 140 . Although the mechanisms underlying these findings remain to be elucidated, it is probable that they arise from a combination of systemic and cell-mediated interactions. Interestingly, obese diabetic BBZDR/Wor rats exhibit increased numbers of marrow adipocytes and impaired innervation of bone marrow stromal elements relative to controls, suggesting a link between obesity and disruption of the multicomponent HSC niche described above 141 . Whether this disruption is a function of specific adipocyt e-mediated local signals (for example, NRP1), of systemic inflammatory signals (for example, transforming growth factor-β), or of a niche interaction that is not yet described, is a topic of great interest for future study.
A look ahead: the HSC niche in therapy Inadequate, impaired, or dysregulated haematopoiesis accounts for a substantial fraction of morbidity and mortality in today's society and, until recently, most therapies have focused somewhat selectively on fixing blood cells and their progenitors directly. The new findings discussed in this Review indicate that haematopoiesis is likely to be driven as much by microenvironmental cues from the niche as by cell-intrinsic ones. There remain many open questions concerning the regulation of haematopoiesis by niche factors. Chief among them is if and how inputs from different niche components are spatially and temporally segregated from the perspective of the HSC. How HSCs influence many of the niche components discussed above is also unknown. Additionally, it is still unclear whether specific niche inputs vary in different bone marrow locations (for example, calvarial niches as compared with femoral diaphyseal niches and femoral metaphyseal niches) and how niche inputs in a given location change over time.
Despite the many unanswered questions, our new understanding of the importance of the microenvironment in haematopoiesis allows the development of novel therapeutic strategies that target the niche in order to correct haematopoietic dysfunction. These studies further highlight the limitations of therapies that are aimed only at HSCs. Already, researchers are developing innovative methods of therapeutically target ing the niche: by creating ectopic niches using biomimetic structures 142, 143 or mesenchymal stem cells 144 ; by creating artificial nichelike environments ex vivo 145, 146 ; and by making use of agents that are known to modulate haematopoiesi s in vivo via the niche 147, 148 . Indeed, there are already many open clinical trials that seek to manipulate the niche in vivo or to reconstitute a synthetic niche in vitro, in the hope of effecting specific therapeutic changes within HSCs. In 2006, a multicenter Phase II clinical trial of para thyroid hormone (PTH; which stimulates bone formation and has been shown to increase HSC numbers endogenously and in transplant models 14 ) administration to patients who received double-unit umbilical cord blood (UCB) transplantation was undertaken (ClinicalTrials.gov identifier: NCT00579722), although that trial was unfortunately halted because it reached an early stopping rule probably unrelated to the PTH therapy. Other trials using prostaglandin E2 (ClinicalTrials.gov identifier: NCT00890500) and Notch ligands (ClinicalTrials.gov identifier: NCT01175785) administered ex vivo to expand UCB stem cells before transplant are actively recruiting, as is a study in which UCB cells are co-cultured on MSCs (ClinicalTrials.gov identifier: NCT00498316). A trial using StemRegenin 1 (REF. 71 ) to expand UCB grafts will open soon, and medications like AMD3100 (ClinicalTrials.gov identifier: NCT00075335) and hepatocyte growth factor 149 are poised to join G-CSF and GM-CSF in the small but potent arsenal of HSPC-mobilizing agents. As these therapies move into clinical practice, however, it will be increasingly important to understand not only how they affect haematopoiesi s but also how they affect the haematopoietic niche. Understanding the composition of the niche and the complex interactions between niche elements and HSCs has never been more critical or timely. Only through a deeper understanding of this intricate support system can we truly learn how to enginee r haematopoiesis to combat haematopoietic disease.
